← All diseases Rare and hereditary disorders

Hereditary ATTR amyloidosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the strongest evidence (80)Meta-analysis (11)Treatment guideline (1)Phase 3 study (30)Randomized trial (23)Systematic review (15)Clinical trial (344)Review article (146)Early study (phase 1 or 2) (7)Case report (135)Laboratory or animal study (8)Commentary or editorial (72) Studies currently recruiting participants only (35)

Filter

Publications (1019)

• Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A multicenter study of clinical predictors of positive pyrophosphate scintigraphy findings in the diagnosis of transthyretin amyloidosis. (2025/01/01) ♡
• Single-center analysis of cardiac amyloidosis using 99m Tc-HMDP imaging for diagnosis and evaluation after tafamidis treatment. (2025/01/01) ♡
• Prognosis of patients with wild-type transthyretin cardiac amyloidosis and non-sustained ventricular tachycardia. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy From Other Cardiomyopathies With Left Ventricular Hypertrophy. (2025/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Optimizing drug therapies in cardiac amyloidosis. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Quantitative muscle MRI combined with AI-based segmentation as a follow-up biomarker for ATTRv patients: A longitudinal pilot study. (2025/01/01) ♡
• Real-life experience with disease-modifying drugs in hereditary transthyretin amyloid polyneuropathy: A clinical and electrophysiological appraisal. (2025/01/01) ♡
• Recovery of right ventricular function in patients with transthyretin cardiac amyloidosis after one-year tafamidis administration. (2025/01/01) ♡
• Misfolding of transthyretin in vivo is controlled by the redox environment and macromolecular crowding. (2025/01/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health-Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis. (2025/01/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials. (2025/01/01) ♡
• Orthogonal and multiplexable genetic perturbations with an engineered prime editor and a diverse RNA array. (2024/12/30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. From Molecular to Radionuclide and Pharmacological Aspects in Transthyretin Cardiac Amyloidosis. (2024/12/27) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prospective Multicenter Screening With High-Sensitivity Cardiac Troponin T for Wild-Type Transthyretin Cardiac Amyloidosis in Outpatient and Community-Based Settings. (2024/12/25) ♡
• Cluster analysis and analysis of risk factors for hereditary transthyretin amyloidosis cardiomyopathy. (2024/12/24) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical differential factors in patients with hereditary transthyretin amyloidosis with Val142Ile and Ser43Asn mutations. (2024/12/20) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Sustained Ventricular Tachycardia as the first presentation of transthyretin amyloid cardiomyopathy. (2024/12/13) ♡
• Management of Hereditary Transthyretin Amyloidosis (ATTRv) Patients and Asymptomatic Carriers in Spain: The EMPATIa Study. (2024/12/13) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. (2024/12/12) ♡
• Arginine: A potential prophylactic supplement for transthyretin amyloidosis. (2024/12/10) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A 68-Year-Old Colombian Man Presenting with Heart Failure and a Diagnosis of Cardiac Transthyretin Amyloidosis. (2024/12/09) ♡
• A Comparative Study of the Electroneurographic Findings in Amyloidotic Polyneuropathy in Patients with Light-Chain Amyloidosis and Glu54Gln Transthyretin Amyloidosis. (2024/12/09) ♡
• ATTRv-V30M amyloid fibrils from heart and nerves exhibit structural homogeneity. (2024/12/05) ♡
• Global longitudinal strain in pre-symptomatic patients with mutation for transthyretin amyloidosis. (2024/12/05) ♡
• Does the structure of transthyretin amyloid fibrils vary depending on the organ of accumulation? (2024/12/05) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing Program. (2024/12/03) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Improving Health Equity Through Standardization and Selective Expansion of Genetic Testing in Transthyretin Amyloidosis. (2024/12/03) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Rare case of wtTTR amyloidosis and MGUS in a patient with lung adenocarcinoma. (2024/12/02) ♡
• Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis - correlation between neurofilament light chain and nerve conduction study. (2024/12/01) ♡
• Single-photon emission computed tomography/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis. (2024/12/01) ♡
• Distinguishing hypertensive cardiomyopathy from cardiac amyloidosis in hypertensive patients with heart failure: a CMR study with histological confirmation. (2024/12/01) ♡
• Neck triangle nerve enlargement in hereditary transthyretin amyloidosis correlates with changes in the autonomic, cardiac, and gastrointestinal systems. (2024/12/01) ♡
• Incidence and predictors of sudden death in patients with cardiac amyloidosis. (2024/12/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction. (2024/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Wild-Type Transthyretin Amyloidosis With 99mTc-PYP Uptake in the Extracardiac Soft Tissues But Not in the Myocardium. (2024/12/01) ♡
• Transthyretin cardiac amyloidosis patients in internal medicine: a 10-year retrospective study. (2024/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Phenotype variability and therapeutic response to Patisiran in patients with hereditary transthyretin amyloidosis: a Belgian real-world experience. (2024/12/01) ♡
• Rare transthyretin gene variants (p.Ala45Thr, p.Val91Ala, p.Phe53Cys, p.Ala101Val, p.Glu109Lys, and p.Phe53Leu): diagnostic pitfalls and clinical characteristics of Polish patients with transthyretin cardiac amyloidosis. (2024/11/28) ♡
• Divergent Total Synthesis of Isoflavone Natural Products and Their Potential as Therapeutic Agents for TTR Amyloidosis. (2024/11/22) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. TTR associated leptomeningeal amyloidosis in a Sri Lankan patient. (2024/11/15) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Cardiac amyloidosis. (2024/11/14) ♡
• Hereditary Transthyretin Amyloidosis Neuropathy with Intracellular Amyloidosis and Inclusions. (2024/11/11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Spectrum of hereditary transthyretin amyloidosis due to T60A(p.Thr80Ala) variant in an Irish Amyloidosis Network. (2024/11/11) ♡
• The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement. (2024/11/08) ♡
• Elucidation of the mechanism of amyloid A and transthyretin formation using mass spectrometry-based absolute quantification. (2024/11/01) ♡
• [Amyloidosis - The pathologist's perspective]. (2024/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Clinical aspects of systemic amyloidosis in 2024]. (2024/11/01) ♡
• Improving genetic testing pathways for transthyretin amyloidosis in France: challenges and strategies. (2024/10/29) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.